Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapyEunice S. Wang, Ramón V. Tiu, Michael Heuser et al.|Blood|2022Cited by 129
Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed <i>FLT3</i>-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction ChemotherapyEunice S. Wang, Ramón V. Tiu, Pau Montesinos et al.|Blood|2021Cited by 20